搔癢症治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球搔癢症治療市場規模達到 96 億美元，預計 2025 年至 2034 年期間的複合年成長率為 4.2%。受異位性皮膚炎、牛皮癬和慢性腎臟病等疾病的推動，慢性搔癢症發病率不斷上升，繼續推動市場擴張。由於搔癢症仍然是一種常見但往往難以治療的症狀，對先進治療方案的需求正在加速成長。全球皮膚病和全身疾病的負擔日益加重，迫使製藥公司不斷創新並擴大其治療組合。老年人口的不斷成長，對慢性搔癢症極為敏感，進一步擴大了市場需求。此外，對可用治療方法的認知提高，加上醫療服務機會的改善，預計將在未來十年推動持續成長。

醫學研究的進步正在改變搔癢症治療的格局，生物製劑和JAK抑制劑等新型藥物帶來了有希望的成果。這些創新療法正在透過解決根本原因而不是僅僅緩解症狀來重塑市場。製藥公司正積極投資研發，以推出能夠長期緩解病情且副作用最小的針對性療法。精準醫療的興起和搔癢相關疾病臨床試驗的擴大為產業參與者創造了新的機會。隨著對以患者為中心的護理的日益重視，公司正致力於開發更有效、更安全和個人化的治療方案。

由於異位性皮膚炎盛行率高且迫切需要標靶治療，2024 年該領域將佔全球市場佔有率的 35.7%。與異位性皮膚炎相關的慢性搔癢嚴重影響生活品質，促使患者和醫療保健提供者尋求更有效的解決方案。新型藥物的開發，包括非類固醇類治療和生物療法，對於擴大治療選擇起到了重要作用。同時，膽汁淤積性搔癢症通常與肝病有關，這進一步加劇了對有效治療方法的需求。搔癢症市場不斷發展，新的治療適應症和先進藥物取得管道的擴大推動了大幅成長。

皮質類固醇仍然是搔癢症治療的主要產品類別，佔了相當大的市場。 2024 年皮質類固醇市場價值為 40 億美元，鞏固了其作為各種搔癢症治療基石的地位。皮質類固醇因其功效而廣受認可，常用於治療皮膚炎和蕁麻疹等疾病。它們有多種劑型，包括外用藥膏、口服藥物和注射劑，確保能夠滿足不同患者的需求。它們的價格低廉且易於獲得，進一步加強了它們的廣泛使用，特別是在需要具有成本效益的治療選擇的地區。

2024 年，美國搔癢症治療市場價值為 36 億美元，由於慢性搔癢症盛行率高且醫療保健體系完善，美國仍佔據主導地位。強大的研發計劃，加上穩定的創新治療方法，繼續推動市場成長。生物製劑、JAK 抑制劑和標靶療法的擴展正在改善治療效果，而個人化醫療的興起正在重塑患者護理。隨著人們越來越關注解決搔癢症的根本原因，美國市場預計將繼續處於治療進步的前沿，在未來幾年推動創新和可及性。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 皮膚病盛行率上升
    • 標靶治療和生物製劑的進展
    • 提高認知度和診斷率
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 生物製劑和標靶治療成本高昂
    • 副作用和安全問題
• 成長潛力分析
• 監管格局
• 管道分析
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 皮質類固醇
• 抗組織胺藥
• 抗促效劑
• 免疫抑制劑
• 鈣調神經磷酸酶抑制劑
• 其他產品

第6章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 異位性皮膚炎
• 過敏性接觸性皮膚炎
• 牛皮癬
• 蕁麻疹
• 其他應用

第7章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Amgen
• Astellas Pharma
• Arcutis Biotherapeutics
• Bristol-Myers Squibb
• Cara Therapeutics
• Eli Lilly And Company
• GSK
• Galderma
• Johnson & Johnson
• Kyowa Kirin
• Novartis AG
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries

The Global Pruritus Therapeutics Market reached USD 9.6 billion in 2024 and is projected to grow at a CAGR of 4.2% between 2025 and 2034. The rising incidence of chronic itching disorders, driven by conditions such as atopic dermatitis, psoriasis, and chronic kidney disease, continues to fuel market expansion. As pruritus remains a common yet often challenging symptom to treat, the demand for advanced therapeutic solutions is accelerating. The increasing burden of dermatologic and systemic conditions worldwide is compelling pharmaceutical companies to innovate and expand their treatment portfolios. The growing geriatric population, a demographic highly susceptible to chronic pruritus, further amplifies market demand. Additionally, heightened awareness regarding available treatments, coupled with improved access to healthcare services, is expected to drive sustained growth over the next decade.

Advancements in medical research are transforming the pruritus therapeutics landscape, with new drug classes such as biologics and JAK inhibitors offering promising results. These innovative treatments are reshaping the market by addressing underlying causes rather than just alleviating symptoms. Pharmaceutical firms are actively investing in research and development to introduce targeted therapies that provide long-term relief with minimal side effects. The rise of precision medicine and the expansion of clinical trials for pruritus-related conditions are creating new opportunities for industry players. With a growing emphasis on patient-centric care, companies are focusing on developing more effective, safer, and personalized treatment options.

The atopic dermatitis segment accounted for 35.7% of the global market share in 2024, driven by its high prevalence and the urgent need for targeted therapies. Chronic itching associated with atopic dermatitis significantly impacts quality of life, pushing patients and healthcare providers to seek more effective solutions. The development of novel medications, including non-steroidal treatments and biologic therapies, has been instrumental in expanding treatment options. Meanwhile, cholestatic pruritus, often linked to liver diseases, has further intensified the demand for effective therapeutics. The pruritus market continues to evolve, with new treatment indications and expanded access to advanced medications driving substantial growth.

Corticosteroids remain the leading product category in pruritus therapeutics, accounting for a significant market share. The corticosteroids segment was valued at USD 4 billion in 2024, cementing its role as a cornerstone treatment for various pruritic conditions. Widely recognized for their efficacy, corticosteroids are commonly used for conditions such as dermatitis and urticaria. Their availability in multiple formulations-including topical creams, oral medications, and injectables-ensures their adaptability for different patient needs. Their affordability and accessibility further reinforce their widespread use, particularly in regions where cost-effective treatment options are essential.

The U.S. Pruritus Therapeutics Market was valued at USD 3.6 billion in 2024, maintaining its dominance due to a high prevalence of chronic pruritus conditions and a well-established healthcare system. Strong research and development initiatives, coupled with a steady pipeline of innovative treatments, continue to propel market growth. The expansion of biologics, JAK inhibitors, and targeted therapies is enhancing treatment outcomes, while the rise of personalized medicine is reshaping patient care. With a growing focus on addressing the root causes of pruritus, the U.S. market is expected to remain at the forefront of therapeutic advancements, driving innovation and accessibility in the years to come.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of dermatological diseases
    • 3.2.1.2 Advancements in targeted therapies and biologics
    • 3.2.1.3 Increasing awareness and diagnosis rates
    • 3.2.1.4 Growing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biologic and targeted therapies
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Antihistamines
• 5.4 Counterirritants
• 5.5 Immunosuppressant
• 5.6 Calcineurin inhibitors
• 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Atopic dermatitis
• 6.3 Allergic contact dermatitis
• 6.4 Psoriasis
• 6.5 Urticaria
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Amgen
• 9.3 Astellas Pharma
• 9.4 Arcutis Biotherapeutics
• 9.5 Bristol-Myers Squibb
• 9.6 Cara Therapeutics
• 9.7 Eli Lilly And Company
• 9.8 GSK
• 9.9 Galderma
• 9.10 Johnson & Johnson
• 9.11 Kyowa Kirin
• 9.12 Novartis AG
• 9.13 Pfizer
• 9.14 Sanofi
• 9.15 Teva Pharmaceutical Industries